EU Nephrologists Foresee Travere/CSL Vifor's FILSPARITM : vi

Data from Spherix Global Insights' second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan),...

Related Keywords

France , China , United Kingdom , Spain , Germany , Italy , Japan , Ionis Roche , Novartis , European Medicines Agency , Spherix Network , Linkedin , Spherix Global Insight , Patient Chart , Iga Nephropathy , Rare Glomerular Diseases , Vera Therapeutics , Chart Dynamix , Global Insights , Spherix Global Insights , Pharmaceuticals , Nephrology , Nephrologist , Ga Nephropathy , Agan , Lomerular Diseases , Gravere , Csl Vifor , Filspari , Sglt2 Inhibitors ,